MARKET WIRECNBC • 2h ago
Here are 3 big things we're watching in the stock market in the week aheadThe market could use a few victories in the days ahead, which will be filled with more earnings, an election, and jobs data.
Why JUNS Stock dropped -5.20% Today — RQD Quant Desk Flash
$2.37 -5.20% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $2.34
Jupiter Neurosciences Inc. (JUNS) carries a Roarable Rating of E (Strong Sell) with 33/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE E • RED ALERT
Cap $3.1M
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $2.34 (-1.13%)🧬 Dilution Drag (+1.28% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (33/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-8.9% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • E
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk D-
Each axis scored 0–20
12M PRICE TARGET CONE-11.4% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for JUNS)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (33/100 Composite)
🔍 WHY JUNS SCORES 33/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Cash Engine Quality+8/20 pts (24% of score)
SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 1.8% Gross Margin
▲ #2 Bullish Driver: SEC 10-K Forensic Risk+8/20 pts (24% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)
Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade D$2.85+1.8% Next Q
41
Q2 (-2Q)Grade E$2.90+2.8% Next Q
38
Q3 (-1Q)Grade E$2.98-20.5% Next Q
36
CurrentGrade E$2.37-8.9% Hist 90D α
33
Trajectory: D (41) → E (33)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a JUNS Turnaround Squeeze
While JUNS currently carries a cautious 33/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($3.16) and Max Pain ($2.49) forces dealer call-delta covering toward $110.25.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $JUNS• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “JUNS Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why JUNS Stock dropped -5.20% Today — RQD Quant Desk Flash
Jupiter Neurosciences Inc. (JUNS) dropped -5.20% to $2.37, trading at 2% of its 52-week range ($2.05 – $105). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 2% of its 52-week range ($2.05 – $105) with RSI-14 at 32.2 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $2.37 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable E (Strong Sell) backed by 1.8% gross margin and $0 annual free cash flow.
Live JUNS Headlines & Catalysts
MARKET WIRECNBC • 3h ago
Democratic Rep. Stevens endorses Rogers over El-Sayed in Michigan Senate electionHaley Stevens had lost the Democratic nomination for Senate in Michigan to Abdul El-Sayed earlier this year.
RISK WATCHReuters • 4h ago
Israeli strikes kill eight people in Gaza - medics say - ReutersIsraeli strikes kill eight people in Gaza - medics say Reuters
MARKET WIREReuters • 5h ago
Russia's FSB says minor detained over park attack threat after US tip-off - ReutersRussia's FSB says minor detained over park attack threat after US tip-off Reuters
MARKET WIREReuters • 6h ago
Iran, Qatari mediators hold third day of talks to end US-Iran war - ReutersIran, Qatari mediators hold third day of talks to end US-Iran war Reuters
CATALYSTReuters • 7h ago
Qatar surges, bucking Gulf market slide on Iran war concerns - ReutersQatar surges, bucking Gulf market slide on Iran war concerns Reuters
MARKET WIREReuters • 7h ago
OPEC+ keeps December oil output targets steady ahead of tougher call for 2027 - ReutersOPEC+ keeps December oil output targets steady ahead of tougher call for 2027 Reuters
MARKET WIREReuters • 7h ago
German ministers pledge tough action after rioters damage stores in Frankfurt - ReutersGerman ministers pledge tough action after rioters damage stores in Frankfurt Reuters
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring JUNS)
- ✓Walkthrough of JUNS's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
JUNS // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -91.66%▲ RESISTANCE BREAKOUT
2026-10-30O $2.40H $2.41L $2.05C $2.37VOL 17.8K
RES: $0.72SUP: $1.80SMA50: $3.16SMA200: $20.56
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
JUNS Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on JUNS today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for JUNS. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for JUNS today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (JUNS)
Health Care Rank #885 of 1016
⚔️ MBIO vs JUNS Full Matrix →
1. Head-to-Head Health Care Peer Comparison (JUNS vs. MBIO, CMND, DCOY, SXTP)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Jupiter Neurosciences Inc. (JUNS) ranks #885 by composite RQD confidence (33/100, grade E) and #978 by equity capitalization ($3.1M). Within this direct 5-issuer industry benchmark cohort, JUNS leads on earnings valuation at N/A trailing P/E, while JUNS leads on capital efficiency and profitability with -35.0% ROIC and 80.6% gross margin. SXTP currently holds the highest overall quantitative score in the immediate peer group at 50/100 (D) compared with JUNS at 33/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| JUNS
ACTIVE
Jupiter Neurosciences Inc. | E | 33/100 | — | 80.6% | -35.0% | -5.20% | $3.1M | Benchmark Subject |
| MBIO Mustang Bio Inc. | D- | 43/100 | — | — | -35.0% | +9.00% | $3.0M | /mbio-vs-juns → |
| CMND Clearmind Medicine Inc. | D | 48/100 | — | — | — | -3.46% | $3.0M | /cmnd-vs-juns → |
| DCOY Decoy Therapeutics Inc. | D | 45/100 | — | — | -35.0% | +11.82% | $2.9M | /dcoy-vs-juns → |
| SXTP 60 Degrees Pharmaceuticals Inc. | D | 50/100 | — | 22.3% | -35.0% | +11.87% | $3.3M | /sxtp-vs-juns → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001679628In its most recent audited fiscal period (FY2025, filed 2025-12-31), Jupiter Neurosciences Inc. (JUNS) reported GAAP revenue of $21.8K (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$8.6M, operating cash flow of -$5.4M, and free cash flow of -$5.4M (-38.4% YoY). On the balance sheet, JUNS closed FY2025 with $5.6M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $21.8K | -$8.6M | -$5.4M | -$5.4M | $5.6M | — |
| FY2024 (FY) | 2024-12-31 | $0 | -$2.4M | -$3.9M | -$3.9M | $6.2M | — |
| FY2023 (FY) | 2023-12-31 | $0 | -$4.8M | -$481.0K | -$481.0K | — | — |
3. JUNS Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs JUNS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-01, Jupiter Neurosciences Inc. (NASDAQ: JUNS) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 33/100 at a spot price of $2.37 (-5.20% 1D, market cap $3.1M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, JUNS ranks #885 in composite RQD confidence.
How does JUNS compare to MBIO and CMND in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), JUNS carries a Roarable E (33/100 RQD), trailing P/E of N/A, gross margin of 80.6%, and ROIC of -35.0%. By comparison, MBIO (Mustang Bio Inc.) holds a D- grade (43/100 RQD, P/E N/A, ROIC -35.0%, cap $3.0M) and CMND (Clearmind Medicine Inc.) posts a D grade (48/100 RQD, P/E N/A, ROIC —, cap $3.0M). Among the 5-stock peer group, JUNS leads on earnings multiple (N/A) while JUNS leads on capital efficiency (-35.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for JUNS?
Per JUNS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001679628), Jupiter Neurosciences Inc. generated $21.8K in revenue, -$8.6M in net income, and -$5.4M in free cash flow against $5.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is JUNS trading relative to its 50-day, 200-day, and 52-week technical levels?
JUNS last traded at $2.37 (-5.20% on volume of 7,416 shares), positioning the stock -25.00% below its 50-day simple moving average ($3.16) and -88.47% below its 200-day simple moving average ($20.56). Across its 52-week range of $2.05 to $105.00, JUNS sits at the 0.3% percentile with a 14-day RSI of 32.2 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($2.07 to $2.67).
JUNS Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is JUNS stock moving today?
Why JUNS Stock dropped -5.20% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.